KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biolife Solutions (BLFS) EBIT Margin (2016 - 2025)

Biolife Solutions (BLFS) has disclosed EBIT Margin for 16 consecutive years, with 7.17% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 358.0% to 7.17% in Q4 2025 year-over-year; TTM through Dec 2025 was 17.26%, a 1126.0% decrease, with the full-year FY2025 number at 17.26%, down 1126.0% from a year prior.
  • EBIT Margin was 7.17% for Q4 2025 at Biolife Solutions, up from 0.32% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 7.17% in Q4 2025 to a low of 289.53% in Q4 2023.
  • A 5-year average of 54.5% and a median of 25.4% in 2022 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -17355bps in 2022, then skyrocketed 29312bps in 2024.
  • Biolife Solutions' EBIT Margin stood at 49.5% in 2021, then plummeted by -342bps to 218.96% in 2022, then plummeted by -32bps to 289.53% in 2023, then soared by 101bps to 3.59% in 2024, then soared by 100bps to 7.17% in 2025.
  • Per Business Quant, the three most recent readings for BLFS's EBIT Margin are 7.17% (Q4 2025), 0.32% (Q3 2025), and 65.47% (Q2 2025).